ID   S40A1_HUMAN             Reviewed;         571 AA.
AC   Q9NP59; Q6FI62; Q7Z4F8; Q8IVB2; Q9NRL0;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   18-JUN-2025, entry version 197.
DE   RecName: Full=Ferroportin {ECO:0000305|PubMed:15692071};
DE   AltName: Full=Ferroportin-1;
DE   AltName: Full=Iron-regulated transporter 1;
DE   AltName: Full=Solute carrier family 40 member 1 {ECO:0000312|HGNC:HGNC:10909};
GN   Name=SLC40A1 {ECO:0000312|HGNC:HGNC:10909};
GN   Synonyms=FPN {ECO:0000303|PubMed:15692071}, FPN1, IREG1, SLC11A3;
GN   ORFNames=MSTP079;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT HFE4 ASP-77.
RX   PubMed=10747949; DOI=10.1074/jbc.m000713200;
RA   Abboud S., Haile D.J.;
RT   "A novel mammalian iron-regulated protein involved in intracellular iron
RT   metabolism.";
RL   J. Biol. Chem. 275:19906-19912(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=10882071; DOI=10.1016/s1097-2765(00)80425-6;
RA   McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D.,
RA   Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W.,
RA   Simpson R.J.;
RT   "A novel duodenal iron-regulated transporter, IREG1, implicated in the
RT   basolateral transfer of iron to the circulation.";
RL   Mol. Cell 5:299-309(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=10693807; DOI=10.1038/35001596;
RA   Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J.,
RA   Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C.,
RA   Lux S.E. IV, Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J.,
RA   Fleming M.D., Andrews N.C., Zon L.I.;
RT   "Positional cloning of zebrafish ferroportin1 identifies a conserved
RT   vertebrate iron exporter.";
RL   Nature 403:776-781(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-133.
RC   TISSUE=Aorta;
RA   Hui R.T., Zhao B., Sheng H., Qin B.M., Liu Y.Q., Liu B., Wang X.Y.,
RA   Xu H.S., Zhang Q., Tong Y.K., Song L., Ji X.J., Liu B.H., Lu H., Chen J.Z.,
RA   Cai M.Q., Zheng W.Y., Teng C.Y., Liu Q., Yu L.T., Lin J., Gong Q.,
RA   Zhang A.M., Gao R.L.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6; 16-129 AND 255-316, AND VARIANT
RP   HFE4 VAL-270.
RX   PubMed=15338274; DOI=10.1007/s00439-004-1166-y;
RA   Zaahl M.G., Merryweather-Clarke A.T., Kotze M.J., van der Merwe S.,
RA   Warnich L., Robson K.J.H.;
RT   "Analysis of genes implicated in iron regulation in individuals presenting
RT   with primary iron overload.";
RL   Hum. Genet. 115:409-417(2004).
RN   [12]
RP   FUNCTION, TRANSPORTER ACTIVITY, MUTAGENESIS OF LEU-170, SUBCELLULAR
RP   LOCATION, AND CHARACTERIZATION OF VARIANTS HFE4 ASP-77 AND GLY-490.
RX   PubMed=15692071; DOI=10.1182/blood-2004-11-4502;
RA   Schimanski L.M., Drakesmith H., Merryweather-Clarke A.T., Viprakasit V.,
RA   Edwards J.P., Sweetland E., Bastin J.M., Cowley D., Chinthammitr Y.,
RA   Robson K.J., Townsend A.R.;
RT   "In vitro functional analysis of human ferroportin (FPN) and
RT   hemochromatosis-associated FPN mutations.";
RL   Blood 105:4096-4102(2005).
RN   [13]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND CAUTION.
RX   PubMed=22178646; DOI=10.1016/j.bbamem.2011.12.002;
RA   Madejczyk M.S., Ballatori N.;
RT   "The iron transporter ferroportin can also function as a manganese
RT   exporter.";
RL   Biochim. Biophys. Acta 1818:651-657(2012).
RN   [14]
RP   SUBCELLULAR LOCATION, FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=24304836; DOI=10.1152/ajpcell.00348.2013;
RA   Mitchell C.J., Shawki A., Ganz T., Nemeth E., Mackenzie B.;
RT   "Functional properties of human ferroportin, a cellular iron exporter
RT   reactive also with cobalt and zinc.";
RL   Am. J. Physiol. 306:C450-C459(2014).
RN   [15]
RP   FUNCTION, TRANSPORTER ACTIVITY, INTERACTION WITH HAMP, UBIQUITINATION, AND
RP   MUTAGENESIS OF LYS-236; LYS-240; LYS-253 AND CYS-326.
RX   PubMed=22682227; DOI=10.1016/j.cmet.2012.03.018;
RA   Qiao B., Sugianto P., Fung E., Del-Castillo-Rueda A., Moran-Jimenez M.J.,
RA   Ganz T., Nemeth E.;
RT   "Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin
RT   ubiquitination.";
RL   Cell Metab. 15:918-924(2012).
RN   [16]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, IDENTIFICATION IN A COMPLEX WITH
RP   STOM, AND SUBUNIT.
RX   PubMed=23219802; DOI=10.1016/j.bbamem.2012.11.030;
RA   Rungaldier S., Oberwagner W., Salzer U., Csaszar E., Prohaska R.;
RT   "Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1 in
RT   human erythrocyte membrane domains.";
RL   Biochim. Biophys. Acta 1828:956-966(2013).
RN   [17]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH
RP   HAMP, MUTAGENESIS OF LYS-240; CYS-326; TYR-501 AND ASP-504, AND
RP   CHARACTERIZATION OF VARIANT HFE4 ASP-144.
RX   PubMed=29237594; DOI=10.1182/blood-2017-05-786590;
RA   Aschemeyer S., Qiao B., Stefanova D., Valore E.V., Sek A.C., Ruwe T.A.,
RA   Vieth K.R., Jung G., Casu C., Rivella S., Jormakka M., Mackenzie B.,
RA   Ganz T., Nemeth E.;
RT   "Structure-function analysis of ferroportin defines the binding site and an
RT   alternative mechanism of action of hepcidin.";
RL   Blood 131:899-910(2018).
RN   [18]
RP   SUBCELLULAR LOCATION, AND CAUTION.
RX   PubMed=29792530; DOI=10.1152/ajpgi.00103.2018;
RA   Thompson K.J., Hein J., Baez A., Sosa J.C., Wessling-Resnick M.;
RT   "Manganese transport and toxicity in polarized WIF-B hepatocytes.";
RL   Am. J. Physiol. 315:G351-G363(2018).
RN   [19]
RP   FUNCTION, TRANSPORTER ACTIVITY, TISSUE SPECIFICITY, AND CHARACTERIZATION OF
RP   VARIANT HIS-248.
RX   PubMed=29599243; DOI=10.1126/science.aal2022;
RA   Zhang D.L., Wu J., Shah B.N., Greutelaers K.C., Ghosh M.C., Ollivierre H.,
RA   Su X.Z., Thuma P.E., Bedu-Addo G., Mockenhaupt F.P., Gordeuk V.R.,
RA   Rouault T.A.;
RT   "Erythrocytic ferroportin reduces intracellular iron accumulation,
RT   hemolysis, and malaria risk.";
RL   Science 359:1520-1523(2018).
RN   [20]
RP   FUNCTION, TRANSPORTER ACTIVITY, MUTAGENESIS OF ARG-88; ASP-157 AND SER-338,
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS HFE4 SER-80; HIS-144
RP   AND CYS-326.
RX   PubMed=30247984; DOI=10.1096/fj.201800831r;
RA   Choi E.K., Nguyen T.T., Iwase S., Seo Y.A.;
RT   "Ferroportin disease mutations influence manganese accumulation and
RT   cytotoxicity.";
RL   FASEB J. 33:2228-2240(2019).
RN   [21]
RP   SUBUNIT, AND UBIQUITINATION.
RX   PubMed=37277838; DOI=10.1186/s12929-023-00934-2;
RA   Baringer S.L., Palsa K., Spiegelman V.S., Simpson I.A., Connor J.R.;
RT   "Apo- and holo-transferrin differentially interact with hephaestin and
RT   ferroportin in a novel mechanism of cellular iron release regulation.";
RL   J. Biomed. Sci. 30:36-36(2023).
RN   [22] {ECO:0007744|PDB:6W4S, ECO:0007744|PDB:6WBV}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.50 ANGSTROMS) IN COMPLEX WITH COBALT,
RP   INTERACTION WITH HAMP, FUNCTION, AND TOPOLOGY.
RX   PubMed=32814342; DOI=10.1038/s41586-020-2668-z;
RA   Billesbolle C.B., Azumaya C.M., Kretsch R.C., Powers A.S., Gonen S.,
RA   Schneider S., Arvedson T., Dror R.O., Cheng Y., Manglik A.;
RT   "Structure of hepcidin-bound ferroportin reveals iron homeostatic
RT   mechanisms.";
RL   Nature 586:807-811(2020).
RN   [23]
RP   VARIANT HFE4 ASP-77.
RX   PubMed=11518736; DOI=10.1172/jci13468;
RA   Montosi G., Donovan A., Totaro A., Garuti C., Pignatti E., Cassanelli S.,
RA   Trenor C.C., Gasparini P., Andrews N.C., Pietrangelo A.;
RT   "Autosomal-dominant hemochromatosis is associated with a mutation in the
RT   ferroportin (SLC11A3) gene.";
RL   J. Clin. Invest. 108:619-623(2001).
RN   [24]
RP   VARIANT HFE4 HIS-144.
RX   PubMed=11431687; DOI=10.1038/90038;
RA   Njajou O.T., Vaessen N., Joosse M., Berghuis B., van Dongen J.W.F.,
RA   Breuning M.H., Snijders P.J.L.M., Rutten W.P.F., Sandkuijl L.A.,
RA   Oostra B.A., van Duijn C.M., Heutink P.;
RT   "A mutation in SLC11A3 is associated with autosomal dominant
RT   hemochromatosis.";
RL   Nat. Genet. 28:213-214(2001).
RN   [25]
RP   VARIANT HFE4 VAL-162 DEL.
RX   PubMed=12091366; DOI=10.1182/blood.v100.2.692;
RA   Wallace D.F., Pedersen P., Dixon J.L., Stephenson P., Searle J.W.,
RA   Powell L.W., Subramaniam V.N.;
RT   "Novel mutation in ferroportin1 is associated with autosomal dominant
RT   hemochromatosis.";
RL   Blood 100:692-694(2002).
RN   [26]
RP   VARIANT HFE4 VAL-162 DEL.
RX   PubMed=12091367; DOI=10.1182/blood-2001-11-0132;
RA   Devalia V., Carter K., Walker A.P., Perkins S.J., Worwood M., May A.,
RA   Dooley J.S.;
RT   "Autosomal dominant reticuloendothelial iron overload associated with a 3-
RT   base pair deletion in the ferroportin 1 gene (SLC11A3).";
RL   Blood 100:695-697(2002).
RN   [27]
RP   VARIANT HFE4 VAL-162 DEL.
RX   PubMed=12123233; DOI=10.1182/blood-2002-03-0693;
RA   Roetto A., Merryweather-Clarke A.T., Daraio F., Livesey K., Pointon J.J.,
RA   Barbabietola G., Piga A., Mackie P.H., Robson K.J.H., Camaschella C.;
RT   "A valine deletion of ferroportin 1: a common mutation in hemochromastosis
RT   type 4.";
RL   Blood 100:733-734(2002).
RN   [28]
RP   VARIANT HFE4 VAL-162 DEL.
RX   PubMed=12406098; DOI=10.1046/j.1365-2141.2002.03946.x;
RA   Cazzola M., Cremonesi L., Papaioannou M., Soriani N., Kioumi A.,
RA   Charalambidou A., Paroni R., Romtsou K., Levi S., Ferrari M., Arosio P.,
RA   Christakis J.;
RT   "Genetic hyperferritinaemia and reticuloendothelial iron overload
RT   associated with a three base pair deletion in the coding region of the
RT   ferroportin gene (SLC11A3).";
RL   Br. J. Haematol. 119:539-546(2002).
RN   [29]
RP   VARIANTS HFE4 GLY-157; HIS-182 AND VAL-323.
RX   PubMed=12730114; DOI=10.1182/blood-2003-02-0439;
RA   Hetet G., Devaux I., Soufir N., Grandchamp B., Beaumont C.;
RT   "Molecular analyses of patients with hyperferritinemia and normal serum
RT   iron values reveal both L ferritin IRE and 3 new ferroportin (SLC11A3)
RT   mutations.";
RL   Blood 102:1904-1910(2003).
RN   [30]
RP   VARIANT HIS-248.
RX   PubMed=14636642; DOI=10.1016/s1079-9796(03)00164-5;
RA   Gordeuk V.R., Caleffi A., Corradini E., Ferrara F., Jones R.A., Castro O.,
RA   Onyekwere O., Kittles R., Pignatti E., Montosi G., Garuti C.,
RA   Gangaidzo I.T., Gomo Z.A.R., Moyo V.M., Rouault T.A., MacPhail P.,
RA   Pietrangelo A.;
RT   "Iron overload in Africans and African-Americans and a common mutation in
RT   the SCL40A1 (ferroportin 1) gene.";
RL   Blood Cells Mol. Dis. 31:299-304(2003).
RN   [31]
RP   VARIANT HFE4 THR-144.
RX   PubMed=12865285; DOI=10.1136/gut.52.8.1215;
RA   Arden K.E., Wallace D.F., Dixon J.L., Summerville L., Searle J.W.,
RA   Anderson G.J., Ramm G.A., Powell L.W., Subramaniam V.N.;
RT   "A novel mutation in ferroportin1 is associated with haemochromatosis in a
RT   Solomon Islands patient.";
RL   Gut 52:1215-1217(2003).
RN   [32]
RP   VARIANT HFE4 ASN-64.
RX   PubMed=12857562;
RA   Rivard S.R., Lanzara C., Grimard D., Carella M., Simard H., Ficarella R.,
RA   Simard R., D'Adamo A.P., De Braekeleer M., Gasparini P.;
RT   "Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a
RT   new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large
RT   French-Canadian family.";
RL   Haematologica 88:824-826(2003).
RN   [33]
RP   VARIANT HFE4 ASP-490.
RX   PubMed=12873829; DOI=10.1016/s0168-8278(03)00148-x;
RA   Jouanolle A.-M., Douabin-Gicquel V., Halimi C., Loreal O., Fergelot P.,
RA   Delacour T., de Lajarte-Thirouard A.-S., Turlin B., Le Gall J.-Y.,
RA   Cadet E., Rochette J., David V., Brissot P.;
RT   "Novel mutation in ferroportin 1 gene is associated with autosomal dominant
RT   iron overload.";
RL   J. Hepatol. 39:286-289(2003).
RN   [34]
RP   VARIANT HFE4 SER-80, AND VARIANT IRON OVERLOAD ILE-174.
RX   PubMed=14757427; DOI=10.1016/j.bcmd.2003.08.003;
RA   Pietrangelo A.;
RT   "The ferroportin disease.";
RL   Blood Cells Mol. Dis. 32:131-138(2004).
RN   [35]
RP   VARIANTS HFE4 ASP-144 AND VAL-270, AND VARIANT IRON OVERLOAD TYR-326.
RX   PubMed=15466004; DOI=10.1136/jmg.2004.020644;
RA   Robson K.J.H., Merryweather-Clarke A.T., Cadet E., Viprakasit V.,
RA   Zaahl M.G., Pointon J.J., Weatherall D.J., Rochette J.;
RT   "Recent advances in understanding haemochromatosis: a transition state.";
RL   J. Med. Genet. 41:721-730(2004).
RN   [36]
RP   ERRATUM OF PUBMED:15466004.
RA   Robson K.J.H., Merryweather-Clarke A.T., Cadet E., Viprakasit V.,
RA   Zaahl M.G., Pointon J.J., Weatherall D.J., Rochette J.;
RL   J. Med. Genet. 41:959-959(2004).
RN   [37]
RP   VARIANTS HFE4 VAL-80; VAL-181 AND ASP-267.
RX   PubMed=16351644; DOI=10.1111/j.1365-2141.2005.05815.x;
RA   Cremonesi L., Forni G.L., Soriani N., Lamagna M., Fermo I., Daraio F.,
RA   Galli A., Pietra D., Malcovati L., Ferrari M., Camaschella C., Cazzola M.;
RT   "Genetic and clinical heterogeneity of ferroportin disease.";
RL   Br. J. Haematol. 131:663-670(2005).
RN   [38]
RP   ERRATUM OF PUBMED:16351644.
RA   Cremonesi L., Forni G.L., Soriani N., Lamagna M., Fermo I., Daraio F.,
RA   Galli A., Pietra D., Malcovati L., Ferrari M., Camaschella C., Cazzola M.;
RL   Br. J. Haematol. 132:806-806(2006).
CC   -!- FUNCTION: Transports Fe(2+) from the inside of a cell to the outside of
CC       the cell, playing a key role for maintaining systemic iron homeostasis
CC       (PubMed:15692071, PubMed:22178646, PubMed:22682227, PubMed:24304836,
CC       PubMed:29237594, PubMed:29599243, PubMed:30247984). Transports iron
CC       from intestinal, splenic, hepatic cells, macrophages and erythrocytes
CC       into the blood to provide iron to other tissues (By similarity).
CC       Controls therefore dietary iron uptake, iron recycling by macrophages
CC       and erythrocytes, and release of iron stores in hepatocytes (By
CC       similarity). When iron is in excess in serum, circulating HAMP/hepcidin
CC       levels increase resulting in a degradation of SLC40A1, thus limiting
CC       the iron efflux to plasma (PubMed:22682227, PubMed:29237594,
CC       PubMed:32814342). {ECO:0000250|UniProtKB:Q9JHI9,
CC       ECO:0000269|PubMed:15692071, ECO:0000269|PubMed:22178646,
CC       ECO:0000269|PubMed:22682227, ECO:0000269|PubMed:24304836,
CC       ECO:0000269|PubMed:29237594, ECO:0000269|PubMed:29599243,
CC       ECO:0000269|PubMed:30247984, ECO:0000269|PubMed:32814342}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Fe(2+)(in) = Fe(2+)(out); Xref=Rhea:RHEA:28486,
CC         ChEBI:CHEBI:29033; Evidence={ECO:0000269|PubMed:15692071,
CC         ECO:0000269|PubMed:22178646, ECO:0000269|PubMed:22682227,
CC         ECO:0000269|PubMed:24304836, ECO:0000269|PubMed:29237594,
CC         ECO:0000269|PubMed:29599243, ECO:0000269|PubMed:30247984};
CC   -!- SUBUNIT: Identified in a complex with STOM (PubMed:23219802). Interacts
CC       with HAMP; affinity of the peptide hormone HAMP for SLC40A1 increases
CC       by 80-fold in the presence of iron and the interaction promotes SLC40A1
CC       ubiquitination and degradation (PubMed:22682227, PubMed:29237594,
CC       PubMed:32814342). Part of a complex composed of SLC40A1/ferroportin,
CC       TF/transferrin and HEPH/hephaestin that transfers iron from cells to
CC       transferrin (PubMed:37277838). {ECO:0000269|PubMed:22682227,
CC       ECO:0000269|PubMed:23219802, ECO:0000269|PubMed:29237594,
CC       ECO:0000269|PubMed:32814342, ECO:0000269|PubMed:37277838}.
CC   -!- INTERACTION:
CC       Q9NP59; P05067: APP; NbExp=5; IntAct=EBI-725153, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10882071,
CC       ECO:0000269|PubMed:15692071, ECO:0000269|PubMed:23219802,
CC       ECO:0000269|PubMed:24304836, ECO:0000269|PubMed:29237594,
CC       ECO:0000269|PubMed:30247984}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:32814342}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:29792530}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:32814342}. Note=Localized to the basolateral
CC       membrane of hepatocytoma WIF-B cells. {ECO:0000269|PubMed:29792530}.
CC   -!- TISSUE SPECIFICITY: Detected in erythrocytes (at protein level)
CC       (PubMed:23219802). Expressed in placenta, intestine, muscle and spleen
CC       (PubMed:10747949). Highly expressed in mature red blood
CC       (PubMed:29599243). {ECO:0000269|PubMed:10747949,
CC       ECO:0000269|PubMed:23219802, ECO:0000269|PubMed:29599243}.
CC   -!- PTM: Polyubiquitinated by RNF217; leading to proteasomal degradation
CC       (By similarity). Under conditions of high systemic iron levels, both
CC       the hormone peptide hepcidin/HAMP and holo(iron bound)-transferrin/TF
CC       induce the ubiquitination, internalization and proteasomal degradation
CC       of SLC40A1 to control iron release from cells (PubMed:22682227,
CC       PubMed:37277838). {ECO:0000250|UniProtKB:Q9JHI9,
CC       ECO:0000269|PubMed:22682227, ECO:0000269|PubMed:37277838}.
CC   -!- DISEASE: Hemochromatosis 4 (HFE4) [MIM:606069]: A disorder of iron
CC       metabolism characterized by iron overload. Excess iron is deposited in
CC       a variety of organs leading to their failure, and resulting in serious
CC       illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy,
CC       arthritis, and hypogonadotropic hypogonadism. Severe effects of the
CC       disease usually do not appear until after decades of progressive iron
CC       loading. {ECO:0000269|PubMed:10747949, ECO:0000269|PubMed:11431687,
CC       ECO:0000269|PubMed:11518736, ECO:0000269|PubMed:12091366,
CC       ECO:0000269|PubMed:12091367, ECO:0000269|PubMed:12123233,
CC       ECO:0000269|PubMed:12406098, ECO:0000269|PubMed:12730114,
CC       ECO:0000269|PubMed:12857562, ECO:0000269|PubMed:12865285,
CC       ECO:0000269|PubMed:12873829, ECO:0000269|PubMed:14757427,
CC       ECO:0000269|PubMed:15338274, ECO:0000269|PubMed:15466004,
CC       ECO:0000269|PubMed:15692071, ECO:0000269|PubMed:16351644,
CC       ECO:0000269|PubMed:29237594, ECO:0000269|PubMed:30247984}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ferroportin (FP) (TC 2.A.100) family. SLC40A
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: Manganese Mn(2+) transport by SLC40A1 remains controversial.
CC       Some in vitro studies have suggested that SLC40A1 transports minimal
CC       amounts of Mn(2+) (PubMed:22178646, PubMed:30247984). Other groups have
CC       suggested that it does not (PubMed:24304836, PubMed:29792530). The
CC       affinity of SLC40A1 for Mn(2+) is extremely low compared with iron,
CC       implying that any SLC40A1-mediated Mn(2+) transport in vivo would
CC       likely be trivial (PubMed:24304836). A recent study examined the role
CC       of SLC40A1 in Mn(2+) homeostasis by using Tmprss6-O mice, which express
CC       high levels of hepcidin/HAMP and therefore have very low SLC40A1 levels
CC       in their tissues. These mice show frank iron deficiency and reduced
CC       iron levels in most tissues, but manganese levels are largely
CC       unaffected (By similarity). These studies suggest that manganese is
CC       propably not the physiological substrate of SLC40A1.
CC       {ECO:0000250|UniProtKB:Q9JHI9, ECO:0000269|PubMed:22178646,
CC       ECO:0000269|PubMed:24304836, ECO:0000269|PubMed:29792530,
CC       ECO:0000269|PubMed:30247984, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF215636; AAF80986.1; -; mRNA.
DR   EMBL; AF231121; AAF44330.1; -; mRNA.
DR   EMBL; AF226614; AAF36697.1; -; mRNA.
DR   EMBL; AL136944; CAB66878.1; -; mRNA.
DR   EMBL; AK314827; BAG37348.1; -; mRNA.
DR   EMBL; CR533564; CAG38595.1; -; mRNA.
DR   EMBL; AC013439; AAX93082.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10902.1; -; Genomic_DNA.
DR   EMBL; BC035893; AAH35893.1; -; mRNA.
DR   EMBL; BC037733; AAH37733.1; -; mRNA.
DR   EMBL; AF171087; AAQ13603.1; -; mRNA.
DR   EMBL; AJ604512; CAE53170.1; -; Genomic_DNA.
DR   EMBL; AJ609539; CAE81347.1; -; Genomic_DNA.
DR   EMBL; AJ609540; CAE81348.1; -; Genomic_DNA.
DR   EMBL; AJ616848; CAE83578.1; -; Genomic_DNA.
DR   EMBL; AJ616847; CAE83578.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS2299.1; -.
DR   RefSeq; NP_055400.1; NM_014585.6.
DR   PDB; 6W4S; EM; 3.20 A; F=1-571.
DR   PDB; 6WBV; EM; 2.50 A; A=1-571.
DR   PDB; 8BZY; EM; 3.24 A; A=2-571.
DR   PDB; 8C02; EM; 4.09 A; A=2-571.
DR   PDB; 8C03; EM; 3.89 A; A=2-571.
DR   PDB; 8DL6; EM; 3.00 A; A=1-571.
DR   PDB; 8DL7; EM; 2.70 A; A=1-571.
DR   PDB; 8DL8; EM; 3.00 A; A=1-571.
DR   PDBsum; 6W4S; -.
DR   PDBsum; 6WBV; -.
DR   PDBsum; 8BZY; -.
DR   PDBsum; 8C02; -.
DR   PDBsum; 8C03; -.
DR   PDBsum; 8DL6; -.
DR   PDBsum; 8DL7; -.
DR   PDBsum; 8DL8; -.
DR   AlphaFoldDB; Q9NP59; -.
DR   EMDB; EMD-16345; -.
DR   EMDB; EMD-16353; -.
DR   EMDB; EMD-16354; -.
DR   EMDB; EMD-21539; -.
DR   EMDB; EMD-21599; -.
DR   EMDB; EMD-27497; -.
DR   EMDB; EMD-27498; -.
DR   EMDB; EMD-27499; -.
DR   SMR; Q9NP59; -.
DR   BioGRID; 119033; 7.
DR   CORUM; Q9NP59; -.
DR   FunCoup; Q9NP59; 967.
DR   IntAct; Q9NP59; 8.
DR   MINT; Q9NP59; -.
DR   STRING; 9606.ENSP00000261024; -.
DR   BindingDB; Q9NP59; -.
DR   ChEMBL; CHEMBL3392948; -.
DR   DrugBank; DB13257; Ferrous sulfate anhydrous.
DR   DrugBank; DB14520; Tetraferric tricitrate decahydrate.
DR   TCDB; 2.A.100.1.4; the ferroportin (fpn) family.
DR   GlyCosmos; Q9NP59; 1 site, No reported glycans.
DR   GlyGen; Q9NP59; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9NP59; -.
DR   PhosphoSitePlus; Q9NP59; -.
DR   BioMuta; SLC40A1; -.
DR   DMDM; 48428687; -.
DR   jPOST; Q9NP59; -.
DR   MassIVE; Q9NP59; -.
DR   PaxDb; 9606-ENSP00000261024; -.
DR   PeptideAtlas; Q9NP59; -.
DR   ProteomicsDB; 81890; -.
DR   ABCD; Q9NP59; 9 sequenced antibodies.
DR   Antibodypedia; 34022; 398 antibodies from 35 providers.
DR   DNASU; 30061; -.
DR   Ensembl; ENST00000261024.7; ENSP00000261024.3; ENSG00000138449.11.
DR   GeneID; 30061; -.
DR   KEGG; hsa:30061; -.
DR   MANE-Select; ENST00000261024.7; ENSP00000261024.3; NM_014585.6; NP_055400.1.
DR   UCSC; uc002uqp.5; human.
DR   AGR; HGNC:10909; -.
DR   CTD; 30061; -.
DR   DisGeNET; 30061; -.
DR   GeneCards; SLC40A1; -.
DR   HGNC; HGNC:10909; SLC40A1.
DR   HPA; ENSG00000138449; Low tissue specificity.
DR   MalaCards; SLC40A1; -.
DR   MIM; 604653; gene.
DR   MIM; 606069; phenotype.
DR   OpenTargets; ENSG00000138449; -.
DR   Orphanet; 648562; Ferroportin disease.
DR   Orphanet; 647834; SLC40A1-related hemochromatosis.
DR   VEuPathDB; HostDB:ENSG00000138449; -.
DR   eggNOG; KOG2601; Eukaryota.
DR   GeneTree; ENSGT00390000015143; -.
DR   HOGENOM; CLU_020370_1_1_1; -.
DR   InParanoid; Q9NP59; -.
DR   OMA; VAMGHVM; -.
DR   OrthoDB; 648861at2759; -.
DR   PAN-GO; Q9NP59; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9NP59; -.
DR   PathwayCommons; Q9NP59; -.
DR   Reactome; R-HSA-425410; Metal ion SLC transporters.
DR   Reactome; R-HSA-5619049; Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages).
DR   Reactome; R-HSA-5619060; Defective CP causes aceruloplasminemia (ACERULOP).
DR   Reactome; R-HSA-5655799; Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum).
DR   Reactome; R-HSA-917937; Iron uptake and transport.
DR   SignaLink; Q9NP59; -.
DR   BioGRID-ORCS; 30061; 16 hits in 1161 CRISPR screens.
DR   ChiTaRS; SLC40A1; human.
DR   GeneWiki; Ferroportin; -.
DR   GenomeRNAi; 30061; -.
DR   Pharos; Q9NP59; Tchem.
DR   PRO; PR:Q9NP59; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NP59; protein.
DR   Bgee; ENSG00000138449; Expressed in pancreatic ductal cell and 188 other cell types or tissues.
DR   ExpressionAtlas; Q9NP59; baseline and differential.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0015093; F:ferrous iron transmembrane transporter activity; IDA:UniProt.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0005381; F:iron ion transmembrane transporter activity; IMP:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017046; F:peptide hormone binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:Ensembl.
DR   GO; GO:0003158; P:endothelium development; IEA:Ensembl.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; IMP:BHF-UCL.
DR   GO; GO:1903988; P:iron ion export across plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0034755; P:iron ion transmembrane transport; IMP:BHF-UCL.
DR   GO; GO:0002260; P:lymphocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0060586; P:multicellular organismal-level iron ion homeostasis; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0060345; P:spleen trabecula formation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   CDD; cd17480; MFS_SLC40A1_like; 1.
DR   Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1.
DR   InterPro; IPR009716; Ferroportin-1.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   PANTHER; PTHR11660; SOLUTE CARRIER FAMILY 40 MEMBER; 1.
DR   PANTHER; PTHR11660:SF47; SOLUTE CARRIER FAMILY 40 MEMBER 1; 1.
DR   Pfam; PF06963; FPN1; 1.
DR   SUPFAM; SSF103473; MFS general substrate transporter; 1.
DR   neXtProt; NX_Q9NP59; -.
DR   PharmGKB; PA35805; -.
DR   TreeFam; TF313463; -.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disease variant; Glycoprotein; Ion transport;
KW   Iron; Iron transport; Membrane; Metal-binding; Proteomics identification;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport;
KW   Ubl conjugation.
FT   CHAIN           1..571
FT                   /note="Ferroportin"
FT                   /id="PRO_0000191310"
FT   TOPO_DOM        1..23
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        24..53
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        54..57
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        58..84
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        85..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        88..118
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        119..126
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        127..162
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        163..164
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        165..195
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        196..202
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        203..229
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        230..306
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        307..333
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        334..338
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        339..366
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        367..368
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        369..391
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        392..453
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        454..483
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        484..488
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        489..513
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        514..516
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   TRANSMEM        517..542
FT                   /note="Helical"
FT                   /evidence="ECO:0000269|PubMed:32814342,
FT                   ECO:0007744|PDB:6W4S"
FT   TOPO_DOM        543..571
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   BINDING         39
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   BINDING         43
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   BINDING         326
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   BINDING         507
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:32814342"
FT   CARBOHYD        434
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         64
FT                   /note="Y -> N (in HFE4; dbSNP:rs1285653301)"
FT                   /evidence="ECO:0000269|PubMed:12857562"
FT                   /id="VAR_030057"
FT   VARIANT         77
FT                   /note="A -> D (in HFE4; loss of iron export function;
FT                   dbSNP:rs28939076)"
FT                   /evidence="ECO:0000269|PubMed:10747949,
FT                   ECO:0000269|PubMed:11518736, ECO:0000269|PubMed:15692071"
FT                   /id="VAR_022594"
FT   VARIANT         80
FT                   /note="G -> S (in HFE4; Reduces protein stability. Loss of
FT                   cell surface localization. Loss of iron export function.
FT                   Increases intracellular manganese; dbSNP:rs978427853)"
FT                   /evidence="ECO:0000269|PubMed:14757427,
FT                   ECO:0000269|PubMed:30247984"
FT                   /id="VAR_030058"
FT   VARIANT         80
FT                   /note="G -> V (in HFE4; dbSNP:rs104893673)"
FT                   /evidence="ECO:0000269|PubMed:16351644"
FT                   /id="VAR_030059"
FT   VARIANT         144
FT                   /note="N -> D (in HFE4; complete loss of HAMP-binding;
FT                   dbSNP:rs104893662)"
FT                   /evidence="ECO:0000269|PubMed:15466004,
FT                   ECO:0000269|PubMed:29237594"
FT                   /id="VAR_030060"
FT   VARIANT         144
FT                   /note="N -> H (in HFE4; Does not affect protein stability.
FT                   Does not affect cell surface localization. Increases iron
FT                   export activity; dbSNP:rs104893662)"
FT                   /evidence="ECO:0000269|PubMed:11431687,
FT                   ECO:0000269|PubMed:30247984"
FT                   /id="VAR_022595"
FT   VARIANT         144
FT                   /note="N -> T (in HFE4; Does not affect protein stability.
FT                   Does not affect cell surface localization. Increases iron
FT                   export activity; dbSNP:rs1434101655)"
FT                   /evidence="ECO:0000269|PubMed:12865285,
FT                   ECO:0000269|PubMed:30247984"
FT                   /id="VAR_030061"
FT   VARIANT         157
FT                   /note="D -> G (in HFE4; Reduces protein stability. Loss of
FT                   cell surface localization. Loss of iron export activity.
FT                   Increases intracellular manganese; dbSNP:rs104893663)"
FT                   /evidence="ECO:0000269|PubMed:12730114,
FT                   ECO:0000269|PubMed:30247984"
FT                   /id="VAR_022596"
FT   VARIANT         162
FT                   /note="Missing (in HFE4)"
FT                   /evidence="ECO:0000269|PubMed:12091366,
FT                   ECO:0000269|PubMed:12091367, ECO:0000269|PubMed:12123233,
FT                   ECO:0000269|PubMed:12406098"
FT                   /id="VAR_022597"
FT   VARIANT         174
FT                   /note="N -> I (in iron overload; dbSNP:rs1397119020)"
FT                   /evidence="ECO:0000269|PubMed:14757427"
FT                   /id="VAR_030062"
FT   VARIANT         181
FT                   /note="D -> V (in HFE4; dbSNP:rs104893672)"
FT                   /evidence="ECO:0000269|PubMed:16351644"
FT                   /id="VAR_030063"
FT   VARIANT         182
FT                   /note="Q -> H (in HFE4; dbSNP:rs104893670)"
FT                   /evidence="ECO:0000269|PubMed:12730114"
FT                   /id="VAR_022598"
FT   VARIANT         248
FT                   /note="Q -> H (associated with mild anemia and a tendency
FT                   to iron loading. Prevents hepcidin/HAMP-induced
FT                   degradation. Protects against severe malaria disease;
FT                   dbSNP:rs11568350)"
FT                   /evidence="ECO:0000269|PubMed:14636642,
FT                   ECO:0000269|PubMed:29599243"
FT                   /id="VAR_020295"
FT   VARIANT         267
FT                   /note="G -> D (in HFE4; dbSNP:rs104893664)"
FT                   /evidence="ECO:0000269|PubMed:16351644"
FT                   /id="VAR_030064"
FT   VARIANT         270
FT                   /note="D -> V (in HFE4; dbSNP:rs368420430)"
FT                   /evidence="ECO:0000269|PubMed:15338274,
FT                   ECO:0000269|PubMed:15466004"
FT                   /id="VAR_030065"
FT   VARIANT         323
FT                   /note="G -> V (in HFE4; dbSNP:rs104893671)"
FT                   /evidence="ECO:0000269|PubMed:12730114"
FT                   /id="VAR_022599"
FT   VARIANT         326
FT                   /note="C -> Y (in iron overload; dbSNP:rs1227198230)"
FT                   /evidence="ECO:0000269|PubMed:15466004"
FT                   /id="VAR_030066"
FT   VARIANT         432
FT                   /note="M -> V (in dbSNP:rs11568355)"
FT                   /id="VAR_020296"
FT   VARIANT         443
FT                   /note="P -> L (in dbSNP:rs45606432)"
FT                   /id="VAR_029299"
FT   VARIANT         490
FT                   /note="G -> D (in HFE4; Loss of iron export activity;
FT                   dbSNP:rs1060501102)"
FT                   /evidence="ECO:0000269|PubMed:12873829,
FT                   ECO:0000269|PubMed:15692071"
FT                   /id="VAR_030067"
FT   VARIANT         561
FT                   /note="R -> G (in dbSNP:rs11568346)"
FT                   /id="VAR_018980"
FT   MUTAGEN         88
FT                   /note="R->G: Reduces protein stability. Loss of cell
FT                   surface localization. Loss of iron export activity.
FT                   Increases intracellular manganese."
FT                   /evidence="ECO:0000269|PubMed:30247984"
FT   MUTAGEN         157
FT                   /note="D->Y: Loss of iron export activity. Loss of cell
FT                   surface localization. Increases intracellular manganese."
FT                   /evidence="ECO:0000269|PubMed:30247984"
FT   MUTAGEN         170
FT                   /note="L->F: Loss of iron export activity."
FT                   /evidence="ECO:0000269|PubMed:15692071"
FT   MUTAGEN         236
FT                   /note="K->R: No loss of ubiquitination; when associated
FT                   with R-253."
FT                   /evidence="ECO:0000269|PubMed:22682227"
FT   MUTAGEN         240
FT                   /note="K->E: Loss of HAMP-induced endocytosis."
FT                   /evidence="ECO:0000269|PubMed:22682227,
FT                   ECO:0000269|PubMed:29237594"
FT   MUTAGEN         253
FT                   /note="K->R: No loss of ubiquitination; when associated
FT                   with R-236."
FT                   /evidence="ECO:0000269|PubMed:22682227"
FT   MUTAGEN         326
FT                   /note="C->S: Complete loss of HAMP-dependent
FT                   ubiquitination. Does not affect protein stability. Does not
FT                   affect cell surface localization."
FT                   /evidence="ECO:0000269|PubMed:22682227,
FT                   ECO:0000269|PubMed:30247984"
FT   MUTAGEN         338
FT                   /note="S->R: Reduces protein stability."
FT                   /evidence="ECO:0000269|PubMed:30247984"
FT   MUTAGEN         501
FT                   /note="Y->C: About 90% loss of HAMP binding."
FT                   /evidence="ECO:0000269|PubMed:29237594"
FT   MUTAGEN         504
FT                   /note="D->N: About 95% loss of HAMP binding."
FT                   /evidence="ECO:0000269|PubMed:29237594"
FT   CONFLICT        130..133
FT                   /note="TSCY -> VSSQ (in Ref. 10; AAQ13603)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324
FT                   /note="F -> S (in Ref. 9; AAH35893)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        430..431
FT                   /note="IY -> RD (in Ref. 1; AAF80986)"
FT                   /evidence="ECO:0000305"
FT   HELIX           17..20
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           24..53
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   TURN            54..56
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           59..85
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           88..115
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           117..122
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           126..155
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           158..162
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   TURN            163..165
FT                   /evidence="ECO:0007829|PDB:8DL6"
FT   HELIX           167..198
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           201..229
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           231..234
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           290..303
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           308..316
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:8DL6"
FT   TURN            324..327
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           328..334
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           339..366
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           369..390
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   STRAND          393..395
FT                   /evidence="ECO:0007829|PDB:8DL8"
FT   STRAND          400..402
FT                   /evidence="ECO:0007829|PDB:8DL7"
FT   HELIX           453..483
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           486..488
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           489..513
FT                   /evidence="ECO:0007829|PDB:6WBV"
FT   HELIX           517..545
FT                   /evidence="ECO:0007829|PDB:6WBV"
SQ   SEQUENCE   571 AA;  62542 MW;  E4D6B5594C904959 CRC64;
     MTRAGDHNRQ RGCCGSLADY LTSAKFLLYL GHSLSTWGDR MWHFAVSVFL VELYGNSLLL
     TAVYGLVVAG SVLVLGAIIG DWVDKNARLK VAQTSLVVQN VSVILCGIIL MMVFLHKHEL
     LTMYHGWVLT SCYILIITIA NIANLASTAT AITIQRDWIV VVAGEDRSKL ANMNATIRRI
     DQLTNILAPM AVGQIMTFGS PVIGCGFISG WNLVSMCVEY VLLWKVYQKT PALAVKAGLK
     EEETELKQLN LHKDTEPKPL EGTHLMGVKD SNIHELEHEQ EPTCASQMAE PFRTFRDGWV
     SYYNQPVFLA GMGLAFLYMT VLGFDCITTG YAYTQGLSGS ILSILMGASA ITGIMGTVAF
     TWLRRKCGLV RTGLISGLAQ LSCLILCVIS VFMPGSPLDL SVSPFEDIRS RFIQGESITP
     TKIPEITTEI YMSNGSNSAN IVPETSPESV PIISVSLLFA GVIAARIGLW SFDLTVTQLL
     QENVIESERG IINGVQNSMN YLLDLLHFIM VILAPNPEAF GLLVLISVSF VAMGHIMYFR
     FAQNTLGNKL FACGPDAKEV RKENQANTSV V
//
